Monitoring of dabigatran therapy using Hemoclot® Thrombin Inhibitor assay in patients with atrial fibrillation

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 1, 2015, Pages 95-100

  Samoš, Matej ^a   Stančiaková, Lucia ^a   Ivanková, Jela ^a   Staško, Ján ^a   Kovář, František ^a   Dobrotová, Miroslava ^a   Galajda, Peter ^a   Kubisz, Peter ^a   Mokáň, Marián ^a  

^a University Hospital in Martin   (Slovakia)

Author keywords

Dabigatran monitoring; Dabigatran therapy; Hemoclot Thrombin Inhibitor assay; Non valvular atrial fibrillation

Indexed keywords

ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN;

AGED; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; BLOOD; DEVICES; DRUG MONITORING; FEMALE; HUMAN; MALE; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84923773890     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1125-y     Document Type: Article

References (19)

1. Camm AJ, Lip GY, De Caterina R et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747
2. Ahmad Y, Lip GY (2013) Warfarin for stroke prevention in atrial fibrillation: time to switch? Int J Clin Pract 67:603–605
3. Conolly SJ, Ezekowitz M, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
4. Tabata E, Yasaka M, Wakugawa Y et al (2013) Increase in the Size of an Intracardiac Thrombus during Dabigatran Therapy (110 mg b.i.d.) in an Acute Cardioembolic Stroke Patient. Cerebrovasc Dis Extra 3:78–80
5. Faust AC, Smith MB, Kawalsky D (2013) Acute ischemic stroke following cardioversion in a patient receiving dabigatran. Ann Pharmacother 47:1368–1371
6. Conway SE (2014) Fatal dabigatran-associated bleeding. Am J Health Syst Pharm 71:360
7. Ramos-Esquivel A, Salazar-Sánchez L (2013) Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin. Thromb Res 132:433–436
8. Gosselin R, Hawes E, Moll S et al (2014) Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels. Am J Clin Pathol 141:262–267
9. ® Summary of Product Characteristics. Boehringer Ingelheim Pharmaceuticals Inc, CT
10. van Ryn J, Stangier J, Haertter S et al (2010) Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127
11. Ferreira J, Ferreira D, Viana-Baptista M et al (2012) Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: answers to Challenging “Real-World” Questions. Thrombosis 2012:867121
12. Stangier J, Feuring M (2012) Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 23:138–143
13. Hankey GJ, Eikelboom JW (2011) Dabigatran Etexilate. A New Oral Thrombin Inhibitor. Circulation 123:1436–1450
14. Curvers J, van de Kerkhof D, Stroobants AK et al (2012) Measuring Direct Thrombin Inhibitors With Routine and Dedicated Coagulation Assays. Which Assay Is Helpful? Am J Clin Pathol 138:551–558
15. Harinstein LM, Morgan JW, Russo N (2013) Treatment of dabigatran-associated bleeding: case report and review of the literature. J Pharm Pract 26:264–269
16. Antovic JP, Skeppholm M, Eintrei J et al (2013) Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 69:1875–1881
17. Hapgood G, Butler J, Malan E et al (2013) The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 110:308–315
18. Huisman MV, Lip GYH, Diener H-C et al (2012) Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 107(5):838–847
19. Reilly PA, Lehr T, Haertter S et al (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 63:321–328